研究室紹介Laboratories

Back
Top > 研究室紹介 > 高次医用科学 > がん薬物療法学((病)化学療法部)

高次医用科学がん薬物療法学((病)化学療法部)

研究室概要

化学療法部は、がんに対する臓器横断的な診療部門として、臓器別診療科と連携しながら質の高いがん薬物治療を行っています。外来化学療法室の運用、がん薬物療法を中心とする入院診療、緩和ケアチームの活動をはじめ、がん薬物療法を専門とする人材の育成、研究、がん診療拠点病院の事業も担当しています。
「抗がん薬を使い慣れている」、「プロトコールを知っている」だけでは、抗がん薬治療ができることにはなりません。質の高いがん薬物療法を実践するためには、臨床薬理や副作用への理解に加え、各臓器のがんの病態に精通し、個々の患者の病態変化に応じて治療方針を判断していく臨床能力が要求されます。化学療法部での教育は、このような理念に基づいています。

研究プロジェクト

 化学療法部では、「臨床薬理学に基づくがん薬物療法の個別化」を共通テーマとして、様々な臨床研究を行っています。また新規抗がん薬の早期開発治験も行っています。

1. 臨床薬理学に基づいた適正ながん薬物療法
 臓器障害時、高齢者やサルコペニアなど、特別な配慮を必要とする患者に対する適正ながん薬物療法について研究を行っています。
 i). 日本人におけるカルボプラチン投与量設定法を検討するために、GFRを実測した上でカルボプラチンクリアランスとの相関を調べた研究(ASCO 2009、研究実績 25)

chemotherapy01.jpg

 ii). 腎機能障害を有する患者におけるGFRとカルボプラチンクリアランスとの相関を調べた研究(ESMO 2014、研究実績 12)

chemotherapy02.jpg

 iii). 肝機能障害を有する患者におけるゲムシタビンの薬物動態解析(日本臨床腫瘍学会 2013、研究実績 7)

chemotherapy03.jpg

 iv). 分子標的薬を長期使用した患者において体組成の変化を調べた研究(日本臨床腫瘍学会 2016、研究実績 5)

ベースライン      4カ月後

chemotherapy04.jpg

2. 薬理遺伝学に基づいたがん薬物療法の個別化
 様々な遺伝子多型とがん薬物療法の効果や副作用の関連について研究を行っています。
3. 抗がん薬による副作用の早期発見
 抗がん薬により生じる特徴的な副作用を早期に発見するための探索的な臨床研究を行っています。
4. 緩和医療における臨床試験
 プラセボ対照無作為化試験など、緩和医療におけるエビデンスの創出に取り組んでいます。
5. 新規抗がん薬の早期開発治験
 化学療法部では分子標的薬や免疫チェックポイント阻害薬などの、新規抗がん薬の早期開発治験を行っています。

教員

構成員名役職所属
安藤 雄一 教授 がん薬物療法学・化学療法学
満間 綾子 特任講師 がん薬物療法学(がんプロ)
前田 修 病院講師 化学療法部
杉下 美保子 病院助教 化学療法部
足立 康則 病院助教 化学療法部
下方 智也 特任助教 がん薬物療法学(がんプロ)
水谷 武史 特任助教 がん薬物療法学(がんプロ)

研究実績

  • 2016年
    1. Ayumu Matsuoka, Osamu Maeda, Takefumi Mizutani, Yasuyuki Nakano, Nobuyuki Tsunoda, Toyone Kikumori, Hidemi Goto, Yuichi Ando. Bevacizumab exacerbates paclitaxel-induced neuropathy: a retrospective cohort study. PLoS One. 2016 Dec 19;11(12):e0168707. doi: 10.1371/journal.pone.0168707.
    2. Bishal Gyawali, Tomoya Shimokata, Masahiko Ando, Kazunori Honda and Yuichi Ando. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. Ann Oncol. 2016 Oct 22. pii: mdw549.
    3. Hironobu Minami, Yuichi Ando, Brigette Buig Yue Ma, Jih-Hsiabg Lee, Hiroyuki Momota, Yutaka Fujiwara, Leung Li, Koichi Fukino, Koji Ito, Takeshi Tajima, Asuka Mori and Chia-Chi Lin. A phase 1, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. Cancer Sci. 2016 Oct;107(10):1477-1483. doi: 10.1111/cas.13022.
    4. Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, Chihiro Kondoh, Naomi Hayashi, Yasushi Yoshino, Naoto Sassa, Yasuyuki Nakano, Momokazu Gotoh, and Yuichi Ando. Long term use of mTOR inhibitors leads to loss of muscle mass. Mol Clin Oncol. 2016 Nov;5(5):641-646.
    5. Ayumu Matsuoka, Ayako Mitsuma, Osamu Maeda, Hiroaki Kajiyama, Hitoshi Kiyoi, Yasuhiro Kodera, Masato Nagino, Hidemi Goto, Yuichi Ando. Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device. Cancer Sci. 2016 Oct;107(10):1453-1457. doi: 10.1111/cas.13010.
    6. Goro Nakayama, Tsutomu Fujii, Kenta Murotani, Keisuke Uehara, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Daisuke Kobayashi, Mitsuro Kanda, Suguru Yamada, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yuichi Ando and Yasuhiro Kodera. Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Sci. 2016 Oct;107(10):1492-1498. doi: 10.1111/cas.13023.
    7. Kazunori Honda, Kyosuke Takeshita, Kenta Murotani, Ayako Mitsuma, Hironori Hayashi, Nobuyuki Tsunoda, Toyone Kikumori, Toyoaki Murohara, Yuichi Ando. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer. Breast Cancer. 2017 Mar;24(2):312-318. doi: 10.1007/s12282-016-0705-4.
    8. Koichiro Watanabe, Satoshi Otsu, Yoshinori Hirashima, Ryotaro Morinaga, Kazuo Nishikawa, Yasushi Hisamatsu, Tomoya Shimokata, Megumi Inada-Inoue, Takashi Shibata, Hiromi Takeuchi, Takahiro Watanabe, Kota Tokushige, Heiko Maacke, Kuniaki Shirao, Yuichi Ando. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Jun;77(6):1157-64. doi: 10.1007/s00280-016-3019-5. Epub 2016 Apr 12.
    9. Masashi Takano, Kaichiro Yamamoto, Tsutomu Tabata, Yuji Minegishi, Takuma Yokoyama, Eiji Hirata, Takeshi Ikeda, Muneaki Shimada, Kouzo Yamada, Satoshi Morita, Yuichi Ando, Yukihiro Okutani, Masahiro Sugihara, Toru Sugiyama, Yasuo Ohashi, and Yuh Sakata. The impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum. Asia Pac J Clin Oncol. 2016 Jun;12(2):115-24. doi: 10.1111/ajco.12453. Epub 2016 Feb 10.
    10. Mihoko Sugishita, Tsuneo Imai, Toyone Kikumori, Ayako Mitsuma, Tomoya Shimokata, Takashi Shibata, Sachi Morita, Megumi Inada-Inoue, Masataka Sawaki, Yoshinori Hasegawa and Yuichi Ando. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.  Breast Cancer 23:195–201, 2016
    11. Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, Hiroaki Tsukuura, Yuichi Ando. Should low-income countries invest in breast cancer screening? Cancer Causes Control (2016). doi:10.1007/s10552-016-0812-8 in press
    12. Bishal Gyawali, Tomoya Shimokata, Kazunori Honda and Yuichi Ando. Chemotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Treat Rev. 2016 Mar;44:10-6. doi: 10.1016/j.ctrv.2016.01.002. Epub 2016 Jan 22.
    13. Ota A, Gyawali B, Matsuoka A, Ando Y. Unconvincing benefit of combination therapy with gefitinib and pemetrexed in advanced non-small-cell lung cancer. J Clin Oncol. 2017 Feb 20;35(6):691-692. doi: 10.1200/JCO.2016.70.4148. Epub 2016 Dec 5.
    14. Bishal Gyawali, Yuichi Ando. Adjuvant Sunitinib for high-risk resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials. Ann Oncol (2016) mdw667. DOI: https://doi.org/10.1093/annonc/mdw667 Published: 19 December 2016
    15. Bishal Gyawali, Akiko Ota, Yuichi Ando. Explanation for the shorter progression-free survival with Nivolumab in Checkmate 057. N Engl J Med. 2016 Feb 4;374(5):493.
    16. Eiko Yamamoto, Kaoru Niimi, Kayo Fujikake, Tetsuya Nishida, Makoto Murata, Ayako Mitsuma, Yuichi Ando and Fumitaka Kikkawa. High‑dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review. Mol Clin Oncol. 2016 Nov;5(5):660-664. Epub 2016 Sep 8.
    17. Osamu Maeda, Kenji Yokota, Naoki Atsuta, Masahisa Katsuno, Masashi Akiyama, Yuichi Ando. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016 Feb;78(1):119-22.
  • 2015年
    1. Takashi Shibata, Tomoki Ebata, Ken-ichi Fujita, Tomoya Shimokata, Osamu Maeda, Ayako Mitsuma, Yasutsuna Sasaki, Masato Nagino and Yuichi Ando. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Cancer Sci. 2016 Feb;107(2):168-72. doi: 10.1111/cas.12851. Epub 2016 Feb 2.
    2. Naomi Hayashi, Yuichi Ando, Bishal Gyawali, Tomoya Shimokata, Osamu Maeda, Masahide Fukaya, Hidemi Goto, Masato Nagino and Yasuhiro Kodera. Low skeletal muscle density is associated with poor survival in patients with metastatic gastric cancer receiving chemotherapy. Oncol Rep. 2016 Mar;35(3):1727-31. doi: 10.3892/or.2015.4475. Epub 2015 Dec 8.
    3. Ayumu Matsuoka, Osamu Maeda, Megumi Inada-Inoue, Eizaburo Ohno, Yoshiki Hirooka, Yukihiro Yokoyama, Tsutomu Fujii, Masato Nagino, Hidemi Goto and Yuichi Ando. FOLFIRINOX-induced reversible dysarthria. Oncol Lett. 2015 Oct;10(4):2662-2664. Epub 2015 Aug 11.
    4. Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato and Makoto Tahara. A subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec;106(12):1714-21. doi: 10.1111/cas.12826. Epub 2015 Nov 2.
    5. Hiroaki Tsukuura, Yuichi Ando, Bishal Gyawali, Masami Matsumoto, Mihoko Sugishita, Kazunori Honda, Hiroshi Urakawa, Osamu Maeda, and Yoshinori Hasegawa. Prophylactic use of antiemetics for prevention of opioidinduced nausea and vomiting: a questionnaire survey among Japanese physicians. J Palliat Med. 2015;18:977-80. doi: 10.1089/jpm.2015.0203.
    6. Hirofumi Mukai, Norikazu Masuda, Hiroshi Ishiguro, Ayako Mitsuma, Takashi Shibata, Jun Yamamura, Masakazu Toi, Aiko Watabe, Akiko Sarashina, Martina Uttenreuther-Fischer, Yuichi Ando. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemother Pharmacol 2015 Oct;76(4):739-50.
    7. Francis Worden, Martin Fassnacht, Yuankai Shi, Tatiana Hadjieva, Françoise Bonichon, Ming Gao, Laura Fugazzola, Yuichi Ando, Yasuhisa Hasegawa, Do Joon Park, Young Kee Shong, Johannes W.A. Smit, John Chung, Christian Kappeler, Gerold Meinhardt, Martin Schlumberger and Marcia S. Brose. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer. 2015 Dec;22(6):877-87. doi: 10.1530/ERC-15-0252.
    8. Kanako Shibata, Yoshinari Yasuda, Ryo Kobayashi, Yuichi Ando, Tomoya Shimokata, Hideki Kamiya, Mutsuharu Hayashi, Shoichi Maruyama, Seiichi Matsui, Makoto Nakao, Teruo Tsuchiya and Hitomi Teramachi. Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1. Clin Exp Nephrol. 2015 Dec;19(6):1107-13. doi: 10.1007/s10157-015-1115-1. Epub 2015 Apr 19.
    9. Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro. Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutational status. Int J Clin Oncol 20:1211–1217, 2015
    10. Wataru Ichikawa, Keisuke Uehara, Keisuke Minamimura, Chihiro Tanaka, Yasumasa Takii, Hideaki Miyauchi, Sotaro Sadahiro, Ken-ichi Fujita, Toshikazu Moriwaki, Masato Nakamura, Takehiro Takahashi, Akihito Tsuji, Katsunori Shinozaki, Satoshi Morita, Yuichi Ando, Yukihiro Okutani, Masahiro Sugihara, Toru Sugiyama, Yasuo Ohashi, Yuh Sakata. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16.
    11. Tomoyo Oguri, Tomoya Shimokata, Isao Ito, Yoshinari Yasuda, Naoto Sassa, Masami Nishiyama, Akinobu Hamada, Yoshinori Hasegawa, and Yuichi Ando. Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol. 2015 Jul;76(1):53-9. doi: 10.1007/s00280-015-2769-9.
    12. Masayuki Umemura, Akio Ito, Yuichi Ando, Kiyofumi Yamada, Yoshifumi Wakiya and Toshitaka Nabeshima. Effects of outside air temperature on the preparation of antineoplastic drug solutions in biological safety cabinets. J Oncol Pharm Pract. Aug;21(4):243-8, 2015
    13. Bishal Gyawali, Naomi Hayashi, Hiroaki Tsukuura, Kazunori Honda, Tomoya Shimokata, Yuichi Ando. Opioid-induced constipation. Scand J Gastroenterol. Scandinavian Journal of Gastroenterology 2015 Nov;50(11):1331-8. doi: 10.3109/00365521.2015.1054423. Epub 2015 Jun 10.
    14. Ayumu Matsuoka, Osamu Maeda and Yuichi Ando. TRIBE study: administration of all three cytotoxic agents is crucial in advanced colorectal cancer. Lancet Oncol. 2015 Dec;16(16):e577. doi: 10.1016/S1470-2045(15)00390-3.
    15. Kazunori Honda, Bishal Gyawali and Yuichi Ando. Reasons for discrepancy between locoregional and distant PFS in the trial of locoregional treatment for metastatic breast cancer. Lancet Oncol. 2015 Dec;16(16):e586. doi: 10.1016/S1470-2045(15)00368-X
    16. Bishal Gyawali, Tomoya Shimokata and Yuichi Ando. Discordance between the results and conclusions of ICON-7. Lancet Oncol. 2015 Oct;16(13):e478. doi: 10.1016/S1470-2045(15)00283-1.
    17. Bishal Gyawali, Tomoya Shimokata, Kazunori Honda and Yuichi Ando. Flaws in the trial design of IFCT-0802. Ann Oncol. 2015 Jun 25. pii: mdv273.
    18. Sachi Morita, Mariko Hiramatsu, Mihoko Sugishita, Bishal Gyawali, Takashi Shibata, Tomoya Shimokata, Hiroshi Urakawa, Ayako Mitsuma, Suzuko Moritani, Toshinobu Kubota, Shu Ichihara and Yuichi Ando. Pazopanib monotherapy in a patient with malignant granular cell tumor that originally arose in the right orbit: a case report. Oncol Lett. 2015 Aug;10(2):972-974. Epub 2015 May 26.
  • 2014年
    1. Toru Nakanishi, Daisuke Aoki, Yoh Watanabe, Yuichi Ando, Naoki Tomotsugu, Yuji Sato, and Toshiaki Saito. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal Cancer. Jpn J Clin Oncol. 2015 May;45(5):422-6. doi: 10.1093/jjco/hyv016. Epub 2015 Feb 10.
    2. Maeda O, Ando T, Ishiguro K, Watanabe O, Miyahara R, Nakamura M, Funasaka K, Kazuhiro F, Ando Y, Goto H. Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer. Mol Clin Oncol. 2014 Nov;2(6):1103-1106. Epub 2014 Jul 4.
    3. Megumi Inada-Inoue, Yuichi Ando, Kenji Kawada, Ayako Mitsuma, Masataka Sawaki, Taro Yokoyama, Yu Sunakawa, Hiroo Ishida, Kazuhiro Araki, Keishi Yamashita, Keiko Mizuno, Fumio Nagashima, Akiko Takekura, Kazuo Nagamatsu, Yasutsuna Sasaki. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol 73:673-83, 2014
    4. Goro Nakayama, Chie Tanaka, Keisuke Uehara, Kiyoshi Ishigure, Hiroyuki Yokoyama, Daisuke Kobayashi, Mituro Kanda, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiro Koike, Shuji Nomoto, Michitaka Fujiwara, Yuichi Ando and Yasuhiro Kodera. The impact of dose/time modification in irinotecan and oxaliplatin based chemotherapies on outcomes in colorectal cancer. Cancer Chemother Pharmacol 2014 Apr;73(4):847-55. doi: 10.1007/s00280-014-2416-x. Epub 2014 Feb 28.
    5. Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt and Toshihiko Doi. A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci 105(3):347-53, 2014
    6. Yuichiro Yoshioka, Keisuke Uehara, Tomoki Ebata, Yukihiro Yokoyama, Ayako Mitsuma, Yuichi Ando and Masato Nagino. Postoperatibe complications following neoadjuvant bevacizumab treatment for for advanced colorectal cancer. Surg Today. 2014 Jul;44(7):1300-6. doi: 10.1007/s00595-013-0686-2. Epub 2013 Aug 14.
    7. Takashi Shibata, Yosuke Minami, Ayako Mitsuma, Sachi Morita, Megumi Inada-Inoue, Tomoyo Oguri, Tomoya Shimokata, Mihoko Sugishita, Tomoki Naoe and Yuichi Ando. Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Int J Clin Oncol 19(2);391-396, 2014
    8. Yaping Shou, Douglas Robinson, Dereck Amakye, Kristine Rose, Yoon-Jae Cho, Keith L. Ligon, Thad Sharp, Asifa Haider, Raj Bandaru, Yuichi Ando, Birgit Geoerger, Francois Doz, David Ashley, Darren Hargrave, Michela Casanova, Jordi Rodon, Anne Thomas, Alain Mita, Tobey MacDonald, Mark Kieran. Five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015 Feb 1;21(3):585-93. doi: 10.1158/1078-0432.CCR-13-1711. Epub 2014 Dec 3.
    9. Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, and Yoshinori Hasegawa. Carboplatin dosing for adult Japanese patients (invited review). Nagoya J Med Sci 76: 1-9, 2014
    10. Ayumu Matsuoka, Osamu Maeda and Yuichi Ando. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. Letter to the editor regarding the Loupakis article of 23-Oct-2014 [correspondence]. N Engl J Med; 372:290-292, 2015
    11. Bishal Gyawali, Hiroaki Tsukuura, Kazunori Honda, Tomoya Shimokata and Yuichi Ando. Some questions on the randomized controlled trial of communication skills training for oncologists. J Clin Oncol 2015 Jan 10;33(2):222. doi: 10.1200/JCO.2014.58.4532. Epub 2014 Dec 1.
    12. Bishal Gyawali, Bishesh Poudyal, Tomoya Shimokata and Yuichi Ando. Cancer care and research in India: what does it mean to Nepal?\" Lancet Oncol. 2014 Jul;15(8):e299-300. doi: 10.1016/S1470-2045(14)70230-X.
    13. Tomoya Shimokata and Yuichi Ando. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer. Lancet Oncol. 2014 Jun;15(7):e249-50. doi: 10.1016/S1470-2045(14)70214-1
    14. Yuji Miura, Chiyo K Imamura, Koya Fukunaga, Yoshihiko Katsuyama, Koichi Suyama, Toshikazu Okaneya, Taisei Mushiroda, Yuichi Ando, Toshimi Takano and Yusuke Tanigawara. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer. 2014 Dec 16;14:964. doi: 10.1186/1471-2407-14-964.
    15. Yasuhito Funahashi, Naoto Sassa, Megumi Inada-Inoue, Yuichi Ando, Yoshihisa Matsukawa and Momokazu Gotoh. Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 Years. Aktuelle Urol. 45(2):132-134, 2014
    16. Osamu Maeda, Takafumi Ando, Kazuhiro Ishiguro, Osamu Watanabe, Ryoji Miyahara, Masanao Nakamura, Kohei Funasaka, Kazuhiro Furukawa, Yuichi Ando, Katsuhiko Kato and Hidemi Goto. A patient with esophageal cancer with bone metastasis who achieved pain relief with repetitive administration of strontium-89 chlorid. Clin J Gastroenterol. 2014 Oct;7(5):387-91.
    17. Osamu Maeda, Takafumi Ando, Kazuhiro Ishiguro, Osamu Watanabe, Ryoji Miyahara, Tomoko Miyata, Keita Itatsu, Yuichi Ando and Hidemi Goto. A case of gastric carcinosarcoma with distant metastasis for which chemotherapy with S-1 plus cisplatin was transiently effective. Int Canc Conf J (2014) 3:252–259
    18. Yuichi Ando. Cytochrome P450 and anticancer drugs. In. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (Cancer Drug Discovery and Development) Michelle A. Rudek, Cindy H. Chau, William Figg, Howard L. McLeod, eds. pp. 273-288. Springer; 2nd ed. 2014 (2014/1/31) ,

研究キーワード

がん薬物療法学、臨床薬理学、薬理遺伝学、医療安全、外来化学療法、緩和医療

大学院入学案内

化学療法部では、臓器横断的ながん薬物療法や緩和医療についての臨床や研究を行っています。臓器横断的な薬物療法の視点から、がん治療を学問として体系化したものが「がん薬物療法学」であり、化学療法部では特定の臓器にこだわることなく臓器横断的なオンザジョブトレーニングを行っています。これは、実際の診療で遭遇する問題や困難を、患者や医療スタッフと喜怒哀楽をともにしながら解決することにより、チーム医療の一員としての自覚が生まれ、科学的で適切ながん薬物療法を実践できるようになると考えているからです。
研究としては上記のように、「臨床薬理学に基づくがん薬物療法の個別化」を共通テーマとして臨床研究を行うとともに、原発臓器を問わない新規抗がん薬の早期開発治験を行っています。